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Conclusion: Core biopsy with a biopsy gun increase the diagnostic 
accuracy with a higher histologic predictive rate and no obvious ad-
ditional risk of complications.
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Metabolic tumor volume predicts disease progression and overall 
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Background: In lung cancer, stage has classically been the most 
important prognostic factor for disease progression and survival. How-
ever, stage may be simply a surrogate for underlying tumor burden. The 
purpose of this study was to assess the prognostic value of pre-treat-
ment tumor volume as measured by FDG-PET imaging.
Methods: We identiﬁed a cohort of 19 patients with lung cancer who 
had staging PET-CT scans prior to any therapy, and adequate follow-
up. Follow-up was complete to the time of progression for 18 of 19 
patients, and to the time of death for 15 of 19 patients. Four patients 
remain alive. We used custom software to segment metabolically active 
tumor regions semi-automatically on PET scans. We determined the 
relationship between time to progression (TTP) and two PET param-
eters: total metabolic tumor volume (MTV), and standardized uptake 
value (SUV).
Results: The median TTP for the cohort was 8.6 months (range 0.7-
25). The median overall survival (OS) was 15 months. The median 
MTV was 27 mL. On multivariate Cox proportional hazards regression 
analysis, an increase in MTV of 25 mL (the difference between the 75th 
and 25thpercentiles) was associated with a 2.6 fold increase in hazard 
of progression, statistically signiﬁcant (p=0.023) after controlling 
for stage, age, KPS, and weight loss. Figure 1 shows the relationship 
between MTV and progression-free survival. Similarly, an increase in 
MTV of 25 mL was associated with a 2.9 fold increase in the hazard 
of death (p=0.0017). We did not ﬁnd a signiﬁcant relationship between 
SUV and TTP or OS.
Conclusions: In this study, high tumor burden assessed by PET MTV 
is a poor prognostic feature in lung cancer independent of stage, age, 
KPS, and weight loss. This may be promising for stratifying patients in 
randomized trials, and ultimately for selecting risk-adapted therapies. 
These results will need to be validated in larger cohorts with longer fol-
low-up, as well as evaluated prospectively.
Figure 1
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Usefulness of fluorodeoxyglucose positron emission tomography 
integrated with computed tomography (FDG-PET/CT) in 
determining the resectability of primary lung cancer
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Background: The integration of computed tomography (CT) and 
FDG-PET provides better speciﬁcity and sensitivity in tumor imaging 
than either component alone. We prospectively evaluated FDG-PET/
CT as a method for determining surgical indications in patients with 
primary lung cancer. 
Methods: Consecutive patients with a diagnosis of primary lung cancer 
based on preoperative cytology or histologic examination in our hospi-
tal were enrolled prospectively. Conventional disease staging was per-
formed using chest CT, abdominal CT, brain magnetic resonance imag-
ing (MRI), and bone scintigraphy. Treatment strategy was determined 
based on conventional staging. Independently, simultaneous PET-stag-
ing was performed based on whole body FDG-PET/CT and brain MRI. 
Results of preoperative PET were compared with surgical specimens of 
hilar and mediastinal lymph nodes. In nonsurgical cases, node (N) and 
metastasis (M) factors diagnosed by PET were evaluated based on the 
clinical course or results from biopsy specimens of speciﬁc sites. 
Results: Twenty men and 22 women, age range, 47 to 87 years (71±10, 
mean±SD), were enrolled. Histology included 27 adenocarcinomas, 10 
squamous cell carcinomas, and 5 small cell carcinomas. Clinical stage 
by conventional staging was c-stages IA or B in 13, IIA or B in 3, IIIA 
in 6, IIIB in 7, and IV in 13. According to the conventional staging, 
16 patients underwent surgery. By PET-staging, 9 cases (21%) were 
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up-staged and 2 cases (5%) were down-staged. In patients with staging 
discrepancy, PET-staging was accurate in 8 cases including undetected 
M1 disease, and conventional staging was accurate in 3 cases, based 
on overdiagnosis of N factor by PET. Synchronous malignant diseases 
(laryngeal cancer and malignant lymphoma) were detected by PET. 
One bronchioloalveolar carcinoma showing focal ground-glass opacity 
on CT was PET negative. PET correctly identiﬁed surgical candidates 
in 13 of 42 cases. In resected cases, one false negative (6%) and 3 false 
positive (19%) lymph node metastases were diagnosed by PET. Since 
the false negative case was microscopic N2 limited to one station, 
curative operation was performed. If we considered PET cN3 disease 
as a surgical contraindication, one surgical candidate would have been 
denied surgery. Maximum standardized uptake value (maxSUV) of 
all primary lesions ranged from 0 to 23.0 (8.1±4.3, mean±SD). The 
maxSUV among surgical cases (6.3±3.5) was smaller than among 
nonsurgical cases (9.3±4.4, p<0.05). The maxSUV was similar among 
the different histologic types.
Conclusions: FDG-PET/CT is useful for determining the clinical stage 
and resectability of primary lung cancer. However, false positive ﬁnd-
ings in regional lymph nodes, possibly due to past infectious diseases, 
are of major concern to be solved. A negative PET study in lymph 
nodes and distant metastases suggests that these patients can proceed 
directly to thoracotomy without mediastinoscopy. The maxSUV was 
related with resectability of primary lung cancer.
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Mammalian target of rapamycin (mTOR) inhibition by RAD001 in 
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Background: RAD001 (everolimus) is a novel inhibitor of mTOR for-
mulated for oral administration, currently investigated as an anticancer 
agent in clinical studies. In preclinical experiments a prominent impact 
of mTOR inhibition on glucose homeostasis was described with the 
transcription factor HIF-1 as one of the primary mediators of RAD001-
induced inhibition of mTOR. Moreover, the inhibition of FDG uptake 
has been demonstrated by FDG-PET imaging in preclinical models 
treated with RAD001. Therefore we reasoned that glucose metabolism 
as measured by FDG-PET might thus serve as a pharmacodynamic 
marker of RAD001 acting on its target in cancer pts. Here we report for 
the ﬁrst time on the use of FDG-PET in evaluation of the pharmacody-
namic effects of RAD001 in pts with recurrent NSCLC.
Patients and Methods: Patients with advanced NSCLC previously 
treated with either chemotherapy only or with chemotherapy and an 
EGFR inhibitor were treated with 10 mg continuous daily dose of 
RAD001 in an open label, multi-centre phase II study. A subgroup of 8 
pts enrolled in 2 of the study centres was evaluated by serial FDG-PET 
scans. FDG-PET was performed at the baseline and on the day 8 of 
treatment in all 8 patients. In addition, in 5 out of these 8 pts FDG-PET 
was performed on the day 28 of treatment. Evaluation of FDG-PET 
scans was performed centrally. The sum of the maximum standardized 
uptake values (sSUVmax) measured in up to 5 lesions was calculated at 
each time point. Percentage change of sSUVmax values from base-
line was calculated on days 8 and 28. In addition, standard computed 
tomography (CT) scans obtained at baseline (8 pts) and on day 28 (6 
pts) were evaluated and the change of the sum of the longest diameter 
of lesions (up to 10 selected lesions including those evaluated by FDG-
PET) was calculated. A lesion by lesion analysis will be presented. 
Results: Reduction of sSUVmax on day 8 was observed in all pts and 
ranged between 1.4% and 89.1%. Reduction of sSUVmax on day 28 
was less pronounced compared to the reduction on day 8.
Changes in sSUVmax (day 8 and day 28) and changes in sums of 
longest diameter of lesions evaluated by CT scans are provided in table 
below.
Patient Change Change Change
Number
sSUVmax  
d8(%)
sSUVmax  
d28(%)
sumCT  
d28(%)
0701-0002 -19.4 1.5 3.3
0701-0003 -1.4 NA NA
0701-0004 -89.1 -82.3 -26.6
0701-0005 -19.2 NA NA
0601-0001 -52.2 -9.7 77.9
0601-0003 -17.4 NA 12.7
0601-0007 -13.0 -2.9 11.1
0601-0009 -20.6 -12.7 -16.7
NA=Not Available Measurements       
Conclusions: Results of this study suggest the value of FDG-PET as 
a tool for early evaluation of the pharmacodynamic effect of mTOR 
inhibitors such as RAD001 in patients with NSCLC. In addition, con-
ﬁrmation of similar results obtained in preclinical models suggests the 
usefulness of FDG-PET in clinical proﬁling of mTOR inhibitors.
Correlation of early pharmacodynamic changes evaluated by FDG-PET 
with clinical effects of RAD001 treatment should be evaluated in larger 
studies.
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Background: CT-guided Transthoracic Needle Aspiration Biopsy 
(TNAB) is widely used as a diagnostic tool in the diagnostic work-
up of thoracic lesions. The reported sensitivity for detection of lung 
neoplastic lesions with CT-guided TNB varies from 68% to 93% with 
